Rigel Pharmaceuticals Statistics
Share Statistics
Rigel Pharmaceuticals has 17.87M
shares outstanding. The number of shares has increased by 1.74%
in one year.
| Shares Outstanding | 17.87M |
| Shares Change (YoY) | 1.74% |
| Shares Change (QoQ) | 1.41% |
| Owned by Institutions (%) | 68.52% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 310 |
| FTD / Avg. Volume | 0.13% |
Short Selling Information
The latest short interest is 1.86M, so 10.57% of the outstanding
shares have been sold short.
| Short Interest | 1.86M |
| Short % of Shares Out | 10.57% |
| Short % of Float | 10.8% |
| Short Ratio (days to cover) | 8.17 |
Valuation Ratios
The PE ratio is 16.91 and the forward
PE ratio is 10.5.
Rigel Pharmaceuticals's PEG ratio is
-0.1.
| PE Ratio | 16.91 |
| Forward PE | 10.5 |
| PS Ratio | 1.65 |
| Forward PS | 1.2 |
| PB Ratio | 89.93 |
| P/FCF Ratio | 9.41 |
| PEG Ratio | -0.1 |
Financial Ratio HistoryEnterprise Valuation
Rigel Pharmaceuticals has an Enterprise Value (EV) of 298.9M.
| EV / Sales | 1.67 |
| EV / EBITDA | 10.48 |
| EV / EBIT | 9.5 |
| EV / FCF | 9.51 |
Financial Position
The company has a current ratio of 2.13,
with a Debt / Equity ratio of 18.24.
| Current Ratio | 2.13 |
| Quick Ratio | 2.04 |
| Debt / Equity | 18.24 |
| Debt / EBITDA | 2.1 |
| Debt / FCF | 1.91 |
| Interest Coverage | 3.06 |
Financial Efficiency
Return on Equity is 531.78% and Return on Invested Capital is 21.28%.
| Return on Equity | 531.78% |
| Return on Assets | 10.66% |
| Return on Invested Capital | 21.28% |
| Revenue Per Employee | $1,106,654.32 |
| Profits Per Employee | $107,932.1 |
| Employee Count | 162 |
| Asset Turnover | 1.09 |
| Inventory Turnover | 3.11 |
Taxes
| Income Tax | 881K |
| Effective Tax Rate | 4.8% |
Stock Price Statistics
The stock price has increased by 61.17% in the
last 52 weeks. The beta is 1.32, so Rigel Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.32 |
| 52-Week Price Change | 61.17% |
| 50-Day Moving Average | 19.18 |
| 200-Day Moving Average | 17.54 |
| Relative Strength Index (RSI) | 56.59 |
| Average Volume (20 Days) | 233,335 |
Income Statement
In the last 12 months, Rigel Pharmaceuticals had revenue of 179.28M
and earned 17.48M
in profits. Earnings per share was 0.99.
| Revenue | 179.28M |
| Gross Profit | 160.63M |
| Operating Income | 24.19M |
| Net Income | 17.48M |
| EBITDA | 28.51M |
| EBIT | 26.28M |
| Earnings Per Share (EPS) | 0.99 |
Full Income StatementBalance Sheet
The company has 56.75M in cash and 59.97M in
debt, giving a net cash position of -3.22M.
| Cash & Cash Equivalents | 56.75M |
| Total Debt | 59.97M |
| Net Cash | -3.22M |
| Retained Earnings | -1.39B |
| Total Assets | 163.98M |
| Working Capital | 71.8M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 31.47M
and capital expenditures -36K, giving a free cash flow of 31.43M.
| Operating Cash Flow | 31.47M |
| Capital Expenditures | -36K |
| Free Cash Flow | 31.43M |
| FCF Per Share | 1.79 |
Full Cash Flow StatementMargins
Gross margin is 89.6%, with operating and profit margins of 13.49% and 9.75%.
| Gross Margin | 89.6% |
| Operating Margin | 13.49% |
| Pretax Margin | 10.24% |
| Profit Margin | 9.75% |
| EBITDA Margin | 15.9% |
| EBIT Margin | 13.49% |
| FCF Margin | 17.53% |
